Each dot is one of the 30 Pharma Services stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 6.4% and the median P/E 28.17. Pinned to the edge: 4 outliers on X and 1 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | TMOThermo Fisher Scientific | 7.2% | 36.21 | $252.30B | Life Sciences Tools |
| 2 | PFEPfizer | -0.2% | 39.16 | $169.63B | Pharmaceuticals |
| 3 | TEVATeva Pharmaceutical Industries | 4.1% | 65.58 | $46.30B | Generic Drugs |
| 4 | IQVIqvia Holdings | 8.2% | 32.90 | $45.24B | Contract Research |
| 5 | ZTSZoetis | 1.5% | 12.87 | $33.67B | Animal Health |
| 6 | WSTWest Pharmaceutical Services | 12.4% | 49.07 | $27.72B | Medical Supplies |
| 7 | LHLabcorp Holdings | 6.4% | 26.68 | $26.75B | Diagnostic Labs |
| 8 | IFFInternational Flavors & Fragrances | -4.6% | 34.35 | $23.91B | Specialty Chemicals |
| 9 | STESteris | 8.4% | 27.78 | $22.36B | Medical Devices |
| 10 | MEDPMedpace Holdings | 20.4% | 36.27 | $18.78B | Contract Research |
| 11 | LDOSLeidos Holdings | 3.4% | 12.79 | $17.60B | Defense |
| 12 | ICLRIcon | 3.7% | 43.70 | $14.37B | Contract Research |
| 13 | DVADavita | 6.4% | 14.10 | $11.95B | Healthcare Services |
| 14 | RDYDr Reddys Laboratories | -10.5% | 31.43 | $11.43B | Generic Drugs |
| 15 | PODDInsulet | 29.4% | 27.16 | $10.19B | Medical Devices |
| 16 | CAICaris Life Sciences | 85.4%OUT | 86.61 | $9.11B | Diagnostic Labs |
| 17 | ALKSAlkermes | 10.8% | 111.59OUT | $7.38B | Pharmaceuticals |
| 18 | LNTHLantheus Holdings | 2.3% | 23.66 | $6.51B | Diagnostic Equipment |
| 19 | LGNDLigand Pharmaceuticals | 54.9% | 30.98 | $6.11B | Biotechnology |
| 20 | LQDALiquidia | 2,234%OUT | 28.55 | $3.96B | Pharmaceuticals |
| 21 | OGNOrganon | -2.5% | 17.27 | $3.61B | Pharmaceuticals |
| 22 | ADMAAdma Biologics | 8.0% | 14.81 | $2.50B | Biotechnology |
| 23 | AMPHAmphastar Pharmaceuticals | 1.0% | 14.07 | $1.11B | Generic Drugs |
| 24 | IARTIntegra Lifesciences Holdings | 0.8% | 71.84 | $934.83M | Medical Devices |
| 25 | MGTXMeiraGTx Holdings | 957.3%OUT | 9.68 | $836.48M | Gene and Cell Therapy |
| 26 | EMBCEmbecta | -7.6% | 4.50 | $394.14M | Medical Devices |
| 27 | WDHWaterdrop | 76.3%OUT | 6.32 | $362.00M | Insurance Brokers |
| 28 | ELTPElite Pharmaceuticals | 33.7% | 4.65 | $263.38M | Generic Drugs |
| 29 | UTMDUtah Medical Products | -7.0% | 22.42 | $235.14M | Medical Devices |
| 30 | PBSVPharma-Bio Serv | 3.3% | 40.97 | $10.31M | Consulting |
Among Pharma Services stocks, the largest companies growing revenue faster than the median (6.4%) while trading below the median P/E (28.17) are Steris (STE), Davita (DVA), Insulet (PODD), Adma Biologics (ADMA) and MeiraGTx Holdings (MGTX). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), International Flavors & Fragrances (IFF), Icon (ICLR) and Dr Reddys Laboratories (RDY).
The median P/E across the 30 Pharma Services stocks plotted is 28.17, with the middle half between 14.28 and 38.44.
The median is 6.4%, with the middle half between 1.1% and 18.4%.
The rank correlation (Spearman) is 0.04, a no meaningful positive relationship: knowing one tells you little about the other.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 4 companies are outliers on Revenue Growth (1y) (TTM) and 1 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry group is included unless you choose primary industry only. Nothing on this page is investment advice.